February 20, 2014—Bayer HealthCare Pharmaceuticals has limited sales of its widely used, genetically engineered multiple sclerosis (MS) drug Betaseron due to inability to meet demand, effective with orders received on or after Jan. 1, the Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) announced on its website today.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register.
Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)